Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          Enter the terms you wish to search for.
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              About
                              Budget
                              HHS FY 2020 Budget in Brief
                              FY 2020 Annual Performance Report
                              FY 2020 - Goal 4 Objective 3
 Navigate to:
  HHS Family of Agencies
                                            
            
            HHS Agencies & Offices
    
                                                  
                              
            
      
      
      
      Regional Offices
    
                                                  
                                            
            
      
      
      
      Advisory Committees, Task Forces & Initiatives
    
                                                  
                              
            
      
      
      
      Organizational Chart
    
                                    
                              
            
      
      
      
      Leadership
    
                                                  
                                                    
            
      
      
      
      Budget & Performance
                                            
            
            FY 2025 Budget in Brief
    
                                                  
                                            
            
      
      
      
      FY 2025 Annual Performance Plan and Report
    
                                                  
                                            
            
      
      
      
      FY 2024 Contingency Staffing Plan
    
                                                  
                                            
            
      
      
      
      FY 2024 Budget in Brief
    
                                                  
                                            
            
      
      
      
      FY 2024 Annual Performance Plan and Report
    
                                                  
                                            
            
      
      
      
      FY 2023 Contingency Staffing Plan
    
                                                  
                                            
            
      
      
      
      FY 2023 Budget in Brief
    
                                                  
                                            
            
      
      
      
      FY 2023 Annual Performance Plan and Report
    
                                                  
                                            
            
      
      
      
      FY 2022 Contingency Staffing Plan
    
                                                  
                                            
            
      
      
      
      FY 2022 Budget in Brief
    
                                                  
                                            
            
      
      
      
      FY 2022 Annual Performance Plan and Report
    
                                                  
                                            
            
      
      
      
      FY 2021 Contingency Staffing Plan
    
                                                  
                                            
            
      
      
      
      FY 2021 Budget in Brief
    
                                                  
                                            
            
      
      
      
      FY 2021 Annual Performance Plan and Report
    
                                                  
                                            
            
      
      
      
      FY 2020 Contingency Staffing Plan
    
                                                  
                                            
            
      
      
      
      FY 2020 Budget in Brief
    
                                                  
                              
            
      
      
      
      FY 2020 Annual Performance Report
    
                                                  
                                            
            
      
      
      
      FY 2019 Contingency Staffing Plan
    
                                                  
                              
            
      
      
      
      FY 2019 Annual Performance Report
    
                                                  
                                                                  
            
      
      
      
      Strategic Plan FY 2022 - 2026
                                            
            
            Message from the Secretary
    
                                                  
                                            
            
      
      
      
      Introduction: About HHS
    
                                                  
                                            
            
      
      
      
      Overview: Strategic Plan FY 2022 - 2026
    
                                                  
                                            
            
      
      
      
      Strategic Goal 1: Protect and Strengthen Equitable Access to High Quality and Affordable Healthcare
    
                                                  
                                            
            
      
      
      
      Strategic Goal 2: Safeguard and Improve National and Global Health Conditions and Outcomes
    
                                                  
                                            
            
      
      
      
      Strategic Goal 3: Strengthen Social Well-Being, Equity, and Economic Resilience
    
                                                  
                                            
            
      
      
      
      Strategic Goal 4: Restore Trust and Accelerate Advancements in Science and Research for All
    
                                                  
                                            
            
      
      
      
      Strategic Goal 5: Advance Strategic Management to Build Trust, Transparency, and Accountability
    
                                                  
                              
            
      
      
      
      Appendix: Plan Updates
    
                                    
                                            
            
      
      
      
      News
    
                                    
                              
            
      
      
      
      I Am HHS
    
                                    
                              
            
      
      
      
      CareersText resize icon

                    




FY 2020 Annual Performance Plan and Report - Goal 4 Objective 3








  
  
    

  
      



Fiscal Year 2020
Released March, 2019

**Topics on this page:** Goal 4. Objective 3 | Objective 4.3 Table of Related Performance Measures

Goal 4. Objective 3:  Advance basic science knowledge and conduct applied prevention and treatment research to improve health and development

HHS conducts, funds, and supports a broad and diverse portfolio of biomedical research in a range of scientific disciplines, including basic and translational research, to augment scientific opportunities and innovation for public health needs.  HHS works to strengthen basic and applied science and treatment pipelines to assess potential health threats and bolster the fundamental science knowledge in these risk areas to expedite the development of therapies.  As described in Strategic Objective 4.2, Expand the capacity of the scientific workforce and infrastructure to support innovative research, research is conducted ethically and responsibly.

The Office of the Secretary leads this objective.  The following divisions are responsible for implementing programs under this strategic objective: ACL, AHRQ, CDC, FDA, NIH, and OASH.

Objective 4.3 Table of Related Performance Measures

By 2023, develop, optimize, and evaluate the effectiveness of nano-enabled immunotherapy (nano-immunotherapy) for one cancer type (Lead Agency - NIH; Measure ID - SRO-2.1)

Fiscal Year
			Target
			Result
			Status**FY 2013**
			N/A
			N/A
			N/A**FY 2014**
			N/A
			N/A
			N/A**FY 2015**
			N/A
			N/A
			N/A**FY 2016**
			N/A
			N/A
			N/A**FY 2017**
			N/A
			N/A
			N/A**FY 2018**
			Optimize properties of 3 nanoformulations for effective delivery and antigen-specific response in immune cells.
			Researchers developed, tested, and optimized, in animal models, 3 unique nanodelivery systems for effective anti-cancer immunotherapeutics.
			Target Met**FY 2019**
			Further optimize top 2 candidate nanoformulations for co-delivery of multiple antigens to enhance anti-tumor response in one animal model.
			12/31/19
			In Progress**FY 2020**
			Further optimize the top candidate nanoformulation for co-delivery of antigens, adjuvants and immuno-modulators and evaluate its efficacy and long-lasting immunity (over 3 months) in preclinical models with established tumors.
			12/31/20
			In ProgressNanoparticles are extremely tiny particles that can coat, attach to, or encapsulate drugs. Nanoparticle drug delivery methods have been shown to alleviate some of the current limitations of and enhance the effectiveness of cancer drugs, which include immunotherapies.  Therefore, NIH has launched several lines of research aiming to enhance existing immunotherapies with nanotechnologies or to facilitate the development of new, more efficacious nano-based immunotherapies.

In FY 2018, NIH-funded researchers developed and/or optimized delivery of nanoparticle-based drug formulations to cancer cells, which resulted in enhanced immune responses.  One research team developed and optimized two unique nanoparticle drug delivery platforms.  Both drug delivery systems cause an immune response that boosts the effectiveness of the immunotherapy tested.  Another research team used nanotechnology to improve the effectiveness of a treatment combination using immunotherapy and radiation to treat cancer.  They engineered a number of antigen-capturing nanoparticles (AC-NPs) and found the AC-NPs significantly improved the efficacy of the immunotherapy tested in a model of melanoma.  In FY 2019 and 2020, NIH will continue to support the optimization and evaluation of novel nanoparticle drug formulations to further the clinical translation of nano-based drugs into medicine for treating cancer.

By 2022, evaluate the safety and effectiveness of 1-3 long-acting strategies for the prevention of HIV (Lead Agency - NIH; Measure ID - SRO-2.9)

Fiscal Year
			Target
			Result
			Status**FY 2013**
			N/A
			N/A
			N/A**FY 2014**
			N/A
			N/A
			N/A**FY 2015**
			N/A
			N/A
			N/A**FY 2016**
			N/A
			N/A
			N/A**FY 2017**
			Strategy 1: Continue enrolling participants into two studies to test the safety, tolerability, and effectiveness of VRC01 as an intravenous prevention strategy.
			Enrollment of participants continued for both studies.
			Target Met**FY 2018**
			Strategy 2: Analyze primary results of a Phase 2a study examining the long-acting injectable, cabotegravir, for the prevention of HIV
			Analysis of primary results has been conducted and results are in press.
			Target Met**FY 2019**
			Strategy 3: Complete final analysis of an open-label extension study that builds on the findings of an earlier trial and aims to assess the continued safety of the dapivirine vaginal ring in a more real-world context and study participants’ adherence
			12/31/19
			In Progress**FY 2020**
			Strategy 1: Complete follow-up of participants in studies testing the safety, tolerability, and effectiveness of VRC01.
			12/31/20
			In ProgressNIH-funded research has led to the identification of highly effective, non-vaccine prevention strategies that have the potential to significantly reduce HIV infection rates around the world.  However, adhering to daily or near-daily dosing has proved challenging for both HIV-infected and uninfected individuals.  Cabotegravir, an investigational drug that is available in long-acting injectable form, has shown promise for HIV prevention.  In FY 2018, an NIH-supported study investigating the safety and acceptability of cabotegravir completed enrollment of 200 HIV-uninfected men and women in 8 cities in the United States and abroad.  The results of the primary analysis are in press (to be published in the open-access journal PLoS Medicine), and the results of the extended phase have been analyzed and were presented at the HIV Research for Prevention 2018 Conference.  This study represents an important next step in determining whether additional research should be done to assess the effectiveness of cabotegravir in preventing HIV infection.  In FY 2019 and 2020, NIH will continue support clinical studies that assess the effectiveness of long-acting prevention strategies.

By 2020, identify risk and protective alleles that lead to one novel therapeutic approach, drug target, or pathway to prevention for late-onset Alzheimer’s disease (Lead Agency - NIH; Measure ID - SRO-5.3)

Fiscal Year
			Target
			Result
			Status**FY 2013**
			N/A
			N/A
			N/A**FY 2014**
			Complete Discovery Phase whole genome sequencing and analysis of 582 family members from 111 families with late onset AD to identify genomic regions associated with increased risk of AD; sequencing of the coding regions of the DNA (whole exome sequencing) of 5,000 cases / 5,000 controls for both risk raising and protective loci; and whole exome sequencing and analysis of one individual from ~1,000 additional AD families to identify regions associated with increased risk or protection from AD.
			Sequencing and an initial level of analysis were completed.
			Target Met**FY 2015**
			Initiate Replication Phase to validate genes / regions of interest identified from case-control and family sequencing in ~50,000 samples from well phenotyped individuals by targeted sequencing and/or genotyping.
			Sample selection for whole genome sequencing on additional multiply affected families was initiated. Planning of the Replication Phase has begun.
			Target Met**FY 2016**
			Begin confirmation of genomic regions of interest identified in the Discovery Phase using samples from the Replication phase.
			

			Begin harmonization of data from Discovery phase datasets with data from Replication Phase for confirmation of regions of interest.
			Sample selection/sequencing Discovery Extension phases completed (4,000 additional whole genomes). Data analysis for Extension Phase initiated. Genomic Center for Alzheimer’s Disease funded (all ADSP quality control and data harmonization).
			Target Met**FY 2017**
			Continue confirmation of genomic regions of interest in the Discovery and Replication phase datasets.
			

			

			Continue harmonization of Discovery Phase and Replication Phase datasets.
			NIH met its target of confirming genomic regions of interest in the Discovery and Replication phase data sets and continues to harmonize the Discovery Phase and Replication Phase data sets.
			Target Met**FY 2018**
			Continue confirmation of genomic regions of interest in the Discovery phase using samples from the Replication phase.
			Continue harmonization of Discovery Phase and Replication Phase datasets.
			Begin analysis of genomic regions of interest in the genomes of minority cohorts.
			NIH continued confirmation of genomic regions of interest in the Discovery Phase using samples from the Replication Phase, continued harmonization of Discovery Phase and Replication Phase datasets, and began analysis of genomes of minority cohorts.
			Target Met**FY 2019**
			Begin analysis of genomic regions of interest in the ADSP Discovery Follow-Up Phase using whole genome sequence data from ethnically diverse cohorts.
			Continue confirmation of genomic regions of interest in the Discovery Phase using samples from the Follow-Up phase.
			Continue harmonization of Discovery Phase and Follow-Up Phase datasets.
			12/31/19
			In Progress**FY 2020**
			Continue analysis of ADSP Discovery Follow-Up Phase in ethnically diverse cohorts. Continue confirmation of genomic regions of interest from Discovery Phase and Discovery Follow-Up Phase in ethnically diverse datasets. Compare data on genomic regions of interest by ethnicity.
			12/31/20
			In ProgressEffective interventions to prevent, delay, and treat Alzheimer’s disease (AD) are urgently needed.  It is estimated that as many as 5.5 million Americans age 65 and older are living with AD, and many more under age 65 are also affected.  Available treatments provide symptomatic relief and may slow symptoms of cognitive decline in some people for a limited time.  However, they do not target the underlying molecular pathways believed to be involved in AD’s development; thus, they neither halt nor reverse disease progression.

In FY 2018, the NIH-supported Alzheimer’s Disease Sequencing Project (ADSP), the overall goal of which is to identify genetic variants associated with risk of and protection from AD, continued to confirm the involvement of previously-implicated genomic regions of interest in development of the disease.  In addition, ADSP initiated additional genomic analysis to include racial and ethnic minority participants in the hopes of identifying risk factors that are associated with those groups.  Using a combination of technologies, ADSP has identified a number of genetic “hubs” that may explain some of the basis for the development of AD.  In FY 2019 and 2020, NIH will continue its efforts to identify risk factor genes associated with the disease.

<< Return to Topics in this Report

Top of page

Goal 4 Objective 4 >>

                    
  


Content created by Office of Budget (OB) Content last reviewed March 29, 2019 Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​